University of California, Riverside
169 Aberdeen Dr, Riverside, CA 92507
Learn How a Student-Led Biotech Startup Landed $750K and Advanced to FDA Filing
Tuesday, April 2
12:00 PM – 1:00 PM
MRB Seminar Room
Lunch Provided
What does it take to launch a biotech startup, secure major funding, and navigate the FDA process—all within two years of graduation? Join us for a compelling Lunch & Learn with Grann Pharmaceuticals, a biotech startup founded by Whittier College alumni that raised $750,000 in seed funding and advanced toward FDA filing with innovative nanotechnology-based therapies.
This session offers real-world insight into early-stage biotech entrepreneurship—perfect for anyone interested in startup life sciences, FDA regulatory strategy, or leveraging contract services to scale a venture efficiently.
Why Attend?
- Hear firsthand how Grann identified funding opportunities and convinced investors to back their nanotech treatments
- Learn what it takes to prepare for FDA filings—from timelines to technical challenges
- Explore how contract services can fill gaps in expertise, staffing, and resources for startups
Grann Pharmaceuticals also offers a menu of contract services for startups needing technical support, making this session valuable for companies looking to outsource specialized biotech work.
Click Here to Reserve Your Seat.
About Grann Pharmaceuticals
Founded in 2022, Grann Pharmaceuticals is a biotechnology company pioneering treatments for diseases caused by genetic abnormalities such as Alzheimer’s, cancer, and rare genetic disorders. Leveraging nanotechnology, Grann aims to restore lost human proteins to improve health outcomes. The company’s work is inspired by co-founder Thomas Lyle Temple’s late grandmother, Grannan, and is backed by recent $750K seed funding and residency at CSU San Marcos’ Infinity Lab. Learn more at grannpharma.com.